Laboratory Corporation of America Holdings ($LH) Stock Forecast: Down 2.6% Today

What is Laboratory Corporation of America Holdings?

Labcorp (NYSE: LH) experienced a significant decline in the market today.

Why is Laboratory Corporation of America Holdings going down?

LH stock is down 2.6% on May 20, 2024 14:35

• Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard retired from Labcorp's board of directors, which potentially led to investor uncertainty.
• Despite the introduction of a new first-trimester preeclampsia screening test, the market did not respond positively to this development.
• The sale of over $420k in company stock by a Labcorp executive may have sparked concerns about insider sentiment and future company performance.
• The overall bearish movement in Labcorp's stock today could be attributed to a combination of key personnel changes, new product launches, and insider selling.

LH Price Chart

LH Technical Analysis

LH News

Labcorp Announces Retirement of Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard from Its Board of Directors

BURLINGTON, N.C., May 16, 2024 — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard have retired from its board of directors at the conclusion of their current terms on May 14, 2024. Dr.

https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-retirement-dr-r-sanders-williams-and-mr-jean

Lancorp Launches First Trimester Preeclampsia Screening Test

WASHINGTON (dpa-AFX) - Laboratory Corporation of America Holdings (LH) also known as Labcorp has recently unveiled a groundbreaking first-trimester preeclampsia screening test in the United States…

https://www.finanznachrichten.de/nachrichten-2024-05/62257372-lancorp-launches-first-trimester-preeclampsia-screening-test-020.htm

Laboratory corp executive sells over $420k in company stock

https://www.investing.com/news/company-news/laboratory-corp-executive-sells-over-420k-in-company-stock-93CH-3443901

https://www.investing.com/news/company-news/laboratory-corp-executive-sells-over-420k-in-company-stock-93CH-3443901

Trending Today

Injective ($INJ) Crypto Forecast: Up 5.7% Today

Toncoin ($TON) Crypto Forecast: Up 5.4% Today

NEO ($NEO) Crypto Forecast: Up 5.1% Today

Floki ($FLOKI) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.3% Today

Litecoin ($LTC) Crypto Forecast: Up 5.0% Today

Arweave ($AR) Crypto Forecast: Up 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Up 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Ethena ($ENA) Crypto Forecast: Up 5.9% Today

Laboratory Corporation of America Holdings Price History

14.02.2024 - LH Stock was down 2.9%

• The appointment of Bryan Riggsbee to CareDx's Board of Directors brings financial expertise and experience from other companies, potentially signaling a strategic advantage for CareDx over LabCorp.
• The insider selling of shares by Mark Schroeder, EVP and President Diagnostics & COO of LabCorp, may have raised concerns among investors about the company's future performance.
• The research report on the Europe Medical Diagnostics Market, including competitive analysis of LabCorp, Quest Diagnostics, and others, could have highlighted potential challenges or increased competition for LabCorp, impacting its stock performance negatively.
• Overall, these factors combined might have contributed to the bearish movement of LabCorp's stock today.

27.05.2023 - LH Stock was down 1.0%

• LH had a strong bearish movement today.
• The article suggests that the predictability of LH's cash flows is less visible, which may have contributed to the market movement.
• The article also mentions that LH's return on capital employed has lagged behind the required rate of return in the last two periods, which could be another factor affecting the stock's performance.

25.03.2024 - LH Stock was down 3.7%

• Labcorp reported its first-quarter results, showing an increase in profit that missed estimates, leading to a decline in its shares despite exceeding earnings expectations.
• The company revised its adjusted earnings and revenue growth guidance range for the fiscal year 2024, potentially disappointing investors.
• Despite a strong first-quarter performance, Labcorp faced high market expectations, resulting in a bearish trend in its stock price.
• The adjustment of the full-year guidance range and missing analyst estimates likely contributed to the negative market sentiment towards Labcorp today.

29.03.2024 - LH Stock was up 2.9%

• Received FDA approval for the nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic for Pfizer's gene therapy to treat Hemophilia B patients.
• Approval signifies a significant advancement in precision medicine and gene therapy, underlining Labcorp's leadership in the field.
• Q1 revenue surpassed forecasts, showing a 4.6% increase driven by organic growth and acquisitions, boosting investor confidence in the company's future prospects.
• Market responded positively to the developments, with investors likely optimistic about Labcorp's sustained success in precision medicine and gene therapy.

15.01.2024 - LH Stock was down 1.1%

• The recent decline in the stock of LH could be attributed to the following factors:
• 1. Lower-than-expected earnings: Labcorp's Q4 earnings were notably lower compared to the same period last year, resulting in a negative EPS. This decline in profitability may have affected investor sentiment and contributed to the bearish market movement.
• 2. Disappointing revenue growth: Although Labcorp reported higher revenue for the fourth quarter and full year compared to the previous year, the growth rate fell short of expectations. This slower revenue growth may have raised concerns among investors about the company's ability to sustain its performance in the future.
• 3. Uncertainty in future earnings: While Labcorp provided guidance for 2024 profit that exceeded Wall Street expectations, the lack of clarity in the earnings forecast could have influenced the bearish market movement. Investors may be cautious about potential challenges or uncertainties that could impact Labcorp's profitability in the coming years.
• 4. Overall market sentiment: The broader market conditions and investor sentiment towards the life sciences sector could have also played a role in Labcorp's stock decline. Factors such as macroeconomic trends, industry competition, and regulatory developments can impact investor confidence and contribute to market fluctuations.

03.06.2023 - LH Stock was down 13.0%

• The bearish movement in LH's stock today could be attributed to the following factors:
• 1. Anticipation of second-quarter financial results: Investors may have been cautious ahead of Labcorp's upcoming financial results announcement. Uncertainty surrounding the company's performance could have led to selling pressure on the stock.
• 2. Market sentiment towards medical research stocks: Despite the potential for growth in the medical research industry, overall market sentiment towards this sector might have been negative today. This negative sentiment could have influenced the bearish movement in LH's stock.
• 3. Lack of positive catalysts: The absence of any specific positive news or developments related to Labcorp may have contributed to the bearish movement. Without any significant catalysts to drive the stock higher, investors may have chosen to sell their positions.
• 4. General market conditions: It's important to consider that broader market conditions and macroeconomic factors can also impact individual stock movements. If the overall market experienced a bearish trend today, it could have influenced LH's stock as well.

20.04.2024 - LH Stock was down 2.6%

• Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard retired from Labcorp's board of directors, which potentially led to investor uncertainty.
• Despite the introduction of a new first-trimester preeclampsia screening test, the market did not respond positively to this development.
• The sale of over $420k in company stock by a Labcorp executive may have sparked concerns about insider sentiment and future company performance.
• The overall bearish movement in Labcorp's stock today could be attributed to a combination of key personnel changes, new product launches, and insider selling.